COMMUNIQUÉS West-GlobeNewswire

Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
01/03/2026
-- - 18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity -- -- March 20, 2026 [...]
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
01/03/2026
SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily Well-Tolerated Across All Doses Studied with an [...]
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting
01/03/2026
– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of - 1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use – – Secondary endpoints also provided strong [...]
OrganTech Defines Minimal Stem Cell Set Enabling Functional Hair Follicle Regeneration In Vitro
01/03/2026
TOKYO, March 01, 2026 (GLOBE NEWSWIRE) -- OrganTech, Inc. announced that its research team has defined a minimal stem cell set required for functional hair follicle regeneration in vitro, establishing a defined cellular [...]
WriteUpp Automated Reminders and Smart Booking Tools Drive Double-Digit Reductions in Healthcare No Show Rates
01/03/2026
WriteUpp practice management platform combines automated SMS reminders and configurable booking rules to help healthcare providers recover lost revenue and keep appointment schedules full LONDON, Feb. 28, 2026 (GLOBE [...]
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting
28/02/2026
Châtillon, France, February 28, 2026 DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting Approximately 83% of children treated with the VIASKIN ® Peanut [...]
DBV Technologies présente des données positives supplémentaires de l’étude de phase 3 VITESSE à l’occasion du congres annuel AAAAI
28/02/2026
Châtillon, France, le 28 février (20 :25 CET) 2026 DBV Technologies présente des données positives supplémentaires de l’étude de phase 3 VITESSE à l’occasion du congres annuel AAAAI Environ 83 % des enfants traités avec [...]
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting
28/02/2026
Bezuclastinib mean TSS reduction deepens to –32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms 99% of patients achieve >50% reduction in serum tryptase at 48 weeks, with [...]
CUKTECH 25SE Power Bank Makes Its Powerful Debut in Malaysia, Setting a New Benchmark for High-Capacity Fast Charging
28/02/2026
KUALA LUMPUR, Malaysia, Feb. 28, 2026 (GLOBE NEWSWIRE) -- CUKTECH, a leading innovator in intelligent charging solutions, today announced the official launch of its highly anticipated CUKTECH 25SE Power Bank in the [...]
Fangzhou and Youcare Pharmaceutical Group Form Strategic Alliance to Advance AI-Driven Chronic Care Services
28/02/2026
BEIJING, Feb. 28, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, has signed a strategic collaboration agreement with [...]
Zealthy ED Platform in 2026 (Including Hardies Sublingual Formulations): Telehealth ED Treatment Options, Compounded Medication Pricing, and What Consumers Should Verify Before Starting
28/02/2026
Informational consumer guide examines Zealthy's online ED treatment model, sublingual Hardies formulations, provider evaluation process, subscription structure, and compounded medication disclosures for men evaluating [...]
Zealthy Hydroquinone 2026: Compounded Prescription Details, Online Dermatology Consultation Pricing, and What Consumers Should Verify Before Starting Treatment
28/02/2026
An informational consumer overview of Zealthy's prescription hydroquinone program, including compounded medication status, FDA context, telehealth dermatology consultation details, subscription and refund terms, side [...]
Sugar Harmony Drops Claims Evaluated: 2026 Report on SugarHarmony Liquid Formula Ingredients, Pricing, and What Consumers Should Verify Before Purchasing
28/02/2026
A 2026 informational consumer evaluation of Sugar Harmony Drops marketing claims, ingredient research context, liquid supplement format considerations, pricing structure, and what consumers should verify before [...]
ReduBurn Thermogenic Resistance Claims Evaluated: Latest Report on Ingredients, Pricing, Refund Terms, and What Consumers Should Verify Before Buying
28/02/2026
Informational 2026 customer report evaluates ReduBurn marketing claims, ingredient transparency, thermogenic resistance framing, pricing structure, published refund terms, and consumer due diligence for men and women. [...]
BreezeMeds GLP-1 Weight Loss 2026: Compounded Semaglutide and Tirzepatide Pricing (From $199), FDA Regulatory Status Examined
28/02/2026
A 2026 Informational Overview of the BreezeMeds Compounded GLP-1 Telehealth Weight Loss Platform, Semaglutide and Tirzepatide Medication Formats, Published Pricing Structure, 503A Compounding Pharmacy Framework, [...]
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
27/02/2026
Company Announcement COPENHAGEN, Denmark; February 27, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 587,495 restricted stock units to members of management and employees [...]
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
27/02/2026
Company Announcement COPENHAGEN, Denmark; February 27, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document [...]
Weight Watchers Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call
27/02/2026
NEW YORK, Feb. 27, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers” or the “Company”) will release its results for the fourth quarter and full year 2025 ended December 31, 2025 before [...]
LeMaitre to Participate at Upcoming Investor Conferences in March
27/02/2026
BURLINGTON, Mass., Feb. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in five upcoming investor conferences in March. Leerink Partners Global [...]

Pages